Parkinson's Drug Reduces Disease Markers in Breakthrough Trial

[staceysack]

sounds promising what do you think?

sciencealert.com/parkinsons...

[park_bear]

This sounds very promising. However, this drug is only in Phase 1 trial and it is many years to get through Phase 2 and Phase 3. In addition, prior attempts at vaccination against malformed alpha synuclein have failed.

[staceysack in reply to park_bear]

Yes I know. It's still exciting that they continue to try new therapies to fight this horrible disease

[Boscoejean in reply to park_bear]

so is that the reason why the trial is only enrolling 8 and only at one location?

[staceysack in reply to Boscoejean]

This was the first trial for this drug. They are moving in to the next phase where they will do trials with more people. I believe the first trial is usually small for drug therapies.

[Boscoejean in reply to staceysack]

okay so it is not on clinicaltrials.gov yet if they have moved beyond level 1

[robinson621]

Sounds good, I hear a lot about the breakthrough developments, then they just disappear.

[Pixelpixie]

hopeful but so was Biogen׳s Butenetap after 3 trials and where are they now?

[jeffreyn in reply to Pixelpixie]

Are you referring to Annovis Bio's Buntanetap? Phase 3 results are due by the end of this month.

[Ctime]

This seems similar to ACImmune's approach of developing a vaccine to sequester or reduce intercellular concentrations of alpha synuclein. acimmune.com/pipeline/clini...

I was skeptical of the whole approach after the early disappointing news about monoclonal antibody infusions (the drugs ending in " ...mab") However the long term studies of prasinezumab now seem to show that it is indeed modestly effective. The people at the clinical trials site I go to who have been administering the infusions agree.

It is great that there is is competition in the vaccine space as it will make it move faster and if the general approach is proved viable by prasinezumab it could come faster.

[staceysack in reply to Ctime]

That's great news as well! I hope you are benefiting from your participation in the trial.

[Ctime in reply to staceysack]

Stacey,

Thanks but unfortunately I was rejected for PADOVA , the follow on for prasinezumab . The same clinic where I did the Buntanetap and Selnoflast studies is also a study site for PADOVA so they have been tracking these people for several years.

[staceysack in reply to Ctime]

I'm sorry to hear that. Did you feel like the other studies were worth your time? Hopefully yet 😀

[Ctime in reply to staceysack]

>worth your time?

That is a complex question that I have written about on other threads. I do not think my disease progression has been directly altered by any drug on the studies I have been involved in. There remains a chance that if Buntanetap or Selnoflast succeed, I would have a chance to get some treatment earlier and at lower cost.

However, in the interim, I have received tremendous care from my neuro team and I find it rewarding to contribute to the overall effort.

[WinnieThePoo]

To the extent it's part of the research effort that will one day bring home the bacon then it's exciting. But it's another a-syn hoover and they have failed consistently to affect the disease.

[DrBruce72]

Sounds hopeful.